Show simple item record

An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium-177-DOTATATE

dc.contributor.authorŞANLI, Yasemin
dc.contributor.authorBÜYÜKKAYA, Fikret
dc.contributor.authorKOVAN, Bilal
dc.contributor.authorÖZKAN, Zeynep Gözde
dc.contributor.authorDEMİR, Bayram
dc.contributor.authorTuncman, Duygu
dc.contributor.authorIŞIK, Emine Göknur
dc.contributor.authorSimsek, Duygu Has
dc.contributor.authorTÜRKMEN, Cüneyt
dc.date.accessioned2021-12-10T12:48:49Z
dc.date.available2021-12-10T12:48:49Z
dc.identifier.citationKOVAN B., ÖZKAN Z. G. , DEMİR B., Tuncman D., IŞIK E. G. , Simsek D. H. , BÜYÜKKAYA F., TÜRKMEN C., ŞANLI Y., "An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium-177-DOTATATE", CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2021
dc.identifier.issn1084-9785
dc.identifier.othervv_1032021
dc.identifier.otherav_d96123b6-89c6-43b5-a7fc-8dcb70776cd1
dc.identifier.urihttp://hdl.handle.net/20.500.12627/174740
dc.identifier.urihttps://doi.org/10.1089/cbr.2021.0071
dc.description.abstractBackground: The aim of this study is to clarify the critical organs that limit treatment scheme and also evaluate the validity of currently used critical organ threshold values in neuroendocrine tumor (NET) patients, receiving peptide receptor radionuclide therapy (PRRT) with Lutetium-177 (Lu-177)-DOTATATE. Thirty-six NET patients (ages 16-73 years) who received Lu-177-DOTATATE treatment were evaluated retrospectively in this study. Dosimetric calculations were made using medical internal radionuclide dose method. For calculation of organ doses, Internal Dose Assessment at Organ Level/Exponential Modelling 1.1 software program was used. Follow-up data were used to determine the organ failure.
dc.language.isoeng
dc.subjectResearch and Theory
dc.subjectRadiology, Nuclear Medicine and Imaging
dc.subjectOncology
dc.subjectRadiological and Ultrasound Technology
dc.subjectPharmacy
dc.subjectDrug Guides
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectNükleer Tıp
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectPharmacology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectReviews and References (medical)
dc.subjectPharmacology (medical)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectRADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME
dc.subjectTıp
dc.titleAn Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium-177-DOTATATE
dc.typeMakale
dc.relation.journalCANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.contributor.firstauthorID2656000


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record